MannKind shares jump on ralinepag inhalation development progress
Updated
Updated · MarketWatch · May 6
MannKind shares jump on ralinepag inhalation development progress
3 articles · Updated · MarketWatch · May 6
The stock rose 39% to $3.98 after MannKind said it had spent six months developing ralinepag DPI for United Therapeutics.
The formulation targets pulmonary arterial hypertension and fibrotic lung diseases for planned non-clinical work and a Phase 1 study under the companies' expanded August 2025 collaboration.
United paid MannKind $5 million in April; MannKind could receive up to $35 million in milestones and 10% royalties. Their earlier deal produced Tyvaso DPI, which generated $1.3 billion in 2025 revenue.
After a successful oral tablet, why is United Therapeutics developing an inhaled version of its blockbuster lung drug?
How will a new inhaler compete against its own highly effective pill for treating the same severe lung disease?